

Bart C Jacobs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6695146/publications.pdf>

Version: 2024-02-01

114
papers

8,480
citations

71102

41
h-index

48315

88
g-index

115
all docs

115
docs citations

115
times ranked

5637
citing authors

#	ARTICLE	IF	CITATIONS
1	Guillain-Barré syndrome. <i>Lancet</i> , The, 2016, 388, 717-727.	13.7	1,076
2	Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. <i>Nature Reviews Neurology</i> , 2014, 10, 469-482.	10.1	752
3	Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. <i>Lancet Neurology</i> , The, 2008, 7, 939-950.	10.2	746
4	Diagnosis and management of Guillain-Barré syndrome in ten steps. <i>Nature Reviews Neurology</i> , 2019, 15, 671-683.	10.1	463
5	A clinical prognostic scoring system for Guillain-Barré syndrome. <i>Lancet Neurology</i> , The, 2007, 6, 589-594.	10.2	311
6	<i>Campylobacter jejuni</i> infections and anti-GM1 antibodies in guillain-barré syndrome. <i>Annals of Neurology</i> , 1996, 40, 181-187.	5.3	291
7	The Guillain-Barré syndrome: a true case of molecular mimicry. <i>Trends in Immunology</i> , 2004, 25, 61-66.	6.8	282
8	Prediction of respiratory insufficiency in Guillain-Barré syndrome. <i>Annals of Neurology</i> , 2010, 67, 781-787.	5.3	224
9	Guillain-Barré syndrome associated with preceding hepatitis E virus infection. <i>Neurology</i> , 2014, 82, 491-497.	1.1	205
10	Miller Fisher anti-GQ1b antibodies: ?-Latrotoxin-like effects on motor end plates. <i>Annals of Neurology</i> , 1999, 45, 189-199.	5.3	203
11	Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. <i>Brain</i> , 2008, 131, 1197-1208.	7.6	202
12	Hepatitis E virus and neurological injury. <i>Nature Reviews Neurology</i> , 2016, 12, 77-85.	10.1	198
13	Regional variation of Guillain-Barré syndrome. <i>Brain</i> , 2018, 141, 2866-2877.	7.6	190
14	Mortality in Guillain-Barré syndrome. <i>Neurology</i> , 2013, 80, 1650-1654.	1.1	177
15	Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. <i>Lancet Neurology</i> , The, 2019, 18, 784-794.	10.2	136
16	Structural Characterization of <i>Campylobacter jejuni</i> Lipooligosaccharide Outer Cores Associated with Guillain-Barrel and Miller Fisher Syndromes. <i>Infection and Immunity</i> , 2007, 75, 1245-1254.	2.2	130
17	Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1105-1110.	1.9	119
18	Clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside. <i>Annals of Neurology</i> , 2000, 47, 314-321.	5.3	107

#	ARTICLE	IF	CITATIONS
19	Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis. <i>Neuroepidemiology</i> , 2019, 52, 161-172.	2.3	105
20	International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome. <i>Journal of the Peripheral Nervous System</i> , 2017, 22, 68-76.	3.1	89
21	Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. <i>Brain</i> , 2003, 126, 2220-2234.	7.6	85
22	A <i>Campylobacter jejuni</i> gene associated with immune-mediated neuropathy. <i>Nature Medicine</i> , 2001, 7, 752-753.	30.7	81
23	Hepatitis E virus infection and acute non-traumatic neurological injury: A prospective multicentre study. <i>Journal of Hepatology</i> , 2017, 67, 925-932.	3.7	80
24	COVID-19 vaccine and Guillain-Barré syndrome: let's not leap to associations. <i>Brain</i> , 2021, 144, 357-360.	7.6	77
25	Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA. <i>Journal of the Neurological Sciences</i> , 2005, 239, 37-44.	0.6	76
26	TLR4-Mediated Sensing of <i>Campylobacter jejuni</i> by Dendritic Cells Is Determined by Sialylation. <i>Journal of Immunology</i> , 2010, 185, 748-755.	0.8	72
27	<i>Campylobacter jejuni</i> Lipooligosaccharides Modulate Dendritic Cell-Mediated T Cell Polarization in a Sialic Acid Linkage-Dependent Manner. <i>Infection and Immunity</i> , 2011, 79, 2681-2689.	2.2	72
28	Treatment dilemmas in Guillain-Barré syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 346-352.	1.9	68
29	Neurological disease in adults with Zika and chikungunya virus infection in Northeast Brazil: a prospective observational study. <i>Lancet Neurology</i> , The, 2020, 19, 826-839.	10.2	68
30	Proximal nerve lesions in early Guillain-Barré syndrome: implications for pathogenesis and disease classification. <i>Journal of Neurology</i> , 2017, 264, 221-236.	3.6	67
31	Antibodies to Heteromeric Glycolipid Complexes in Guillain-Barré Syndrome. <i>PLoS ONE</i> , 2013, 8, e82337.	2.5	60
32	<i>Mycoplasma pneumoniae</i> triggering the Guillain-Barré syndrome: A case-control study. <i>Annals of Neurology</i> , 2016, 80, 566-580.	5.3	58
33	Current treatment practice of Guillain-Barré syndrome. <i>Neurology</i> , 2019, 93, e59-e76.	1.1	57
34	Subclass IgG to motor gangliosides related to infection and clinical course in Guillain-Barré syndrome. <i>Journal of Neuroimmunology</i> , 2008, 194, 181-190.	2.3	55
35	Guillain-Barré Syndrome and Adjuvanted Pandemic Influenza A (H1N1) 2009 Vaccines: A Multinational Self-Controlled Case Series in Europe. <i>PLoS ONE</i> , 2014, 9, e82222.	2.5	53
36	Paraparetic Guillain-Barré syndrome. <i>Neurology</i> , 2014, 82, 1984-1989.	1.1	53

#	ARTICLE	IF	CITATIONS
37	Tracheostomy or Not: Prediction of Prolonged Mechanical Ventilation in Guillain-Barré Syndrome. <i>Neurocritical Care</i> , 2017, 26, 6-13.	2.4	52
38	Antibody Responses to <i>Mycoplasma pneumoniae</i> : Role in Pathogenesis and Diagnosis of Encephalitis?. <i>PLoS Pathogens</i> , 2014, 10, e1003983.	4.7	49
39	Skewed Fc Glycosylation Profiles of Anti-proteinase 3 Immunoglobulin G1 Autoantibodies from Granulomatosis with Polyangiitis Patients Show Low Levels of Bisection, Galactosylation, and Sialylation. <i>Journal of Proteome Research</i> , 2015, 14, 1657-1665.	3.7	49
40	Antecedent infections in Guillain-Barré syndrome: a single-center, prospective study. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2510-2517.	3.7	48
41	Association of Albumin Levels With Outcome in Intravenous Immunoglobulin-Treated Guillain-Barré Syndrome. <i>JAMA Neurology</i> , 2017, 74, 189.	9.0	46
42	Diagnosis of Guillain-Barré syndrome in children and validation of the Brighton criteria. <i>Journal of Neurology</i> , 2017, 264, 856-861.	3.6	42
43	Guillain-Barré syndrome related to Zika virus infection: A systematic review and meta-analysis of the clinical and electrophysiological phenotype. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008264.	3.0	41
44	Origin of ganglioside complex antibodies in Guillain-Barré syndrome. <i>Journal of Neuroimmunology</i> , 2007, 188, 69-73.	2.3	39
45	Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study. <i>Brain</i> , 2021, 144, 3392-3404.	7.6	39
46	Guillain-Barré syndrome following varicella-zoster virus infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 511-518.	2.9	36
47	Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): Protocol for a double-blind randomized, placebo-controlled clinical trial. <i>Journal of the Peripheral Nervous System</i> , 2018, 23, 210-215.	3.1	36
48	Clinical outcome of Guillain-Barré syndrome after prolonged mechanical ventilation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 949-954.	1.9	35
49	Innate immunity to <i>Campylobacter jejuni</i> in Guillain-Barré Syndrome. <i>Annals of Neurology</i> , 2015, 78, 343-354.	5.3	34
50	Original research: Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 113-121.	1.9	34
51	Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2021, 20, 275-283.	10.2	34
52	High Incidence of Guillain-Barre Syndrome in Children, Bangladesh. <i>Emerging Infectious Diseases</i> , 2011, 17, 1317-1318.	4.3	30
53	Guillain-Barré syndrome in Bangladesh: validation of Brighton criteria. <i>Journal of the Peripheral Nervous System</i> , 2016, 21, 345-351.	3.1	30
54	Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	6.0	30

#	ARTICLE	IF	CITATIONS
55	High mortality from Guillain-Barré syndrome in Bangladesh. <i>Journal of the Peripheral Nervous System</i> , 2017, 22, 121-126.	3.1	29
56	Guillain-Barré syndrome in low-income and middle-income countries: challenges and prospects. <i>Nature Reviews Neurology</i> , 2021, 17, 285-296.	10.1	29
57	Guillain-Barré syndrome in Denmark: a population-based study on epidemiology, diagnosis and clinical severity. <i>Journal of Neurology</i> , 2019, 266, 440-449.	3.6	27
58	Chemoenzymatic Synthesis of <i>Campylobacter jejuni</i> Lipo-oligosaccharide Core Domains to Examine Guillain-Barré Syndrome Serum Antibody Specificities. <i>Journal of the American Chemical Society</i> , 2020, 142, 19611-19621.	13.7	27
59	Microarray screening of Guillain-Barré syndrome sera for antibodies to glycolipid complexes. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e284.	6.0	25
60	Zika virus infection in the returning traveller: what every neurologist should know. <i>Practical Neurology</i> , 2018, 18, 271-277.	1.1	25
61	Guillain-Barré syndrome during the Zika virus outbreak in Northeast Brazil: An observational cohort study. <i>Journal of the Neurological Sciences</i> , 2021, 420, 117272.	0.6	24
62	Guillain-Barré syndrome: expanding the concept of molecular mimicry. <i>Trends in Immunology</i> , 2022, 43, 296-308.	6.8	24
63	Prevalence, specificity and functionality of anti-ganglioside antibodies in neuropathy associated with IgM monoclonal gammopathy. <i>Journal of Neuroimmunology</i> , 2014, 268, 89-94.	2.3	23
64	Misdiagnosis and diagnostic pitfalls of chronic inflammatory demyelinating polyradiculoneuropathy. <i>European Journal of Neurology</i> , 2021, 28, 2065-2073.	3.3	23
65	Small volume plasma exchange for Guillain-Barré syndrome in resource-limited settings: a phase II safety and feasibility study. <i>BMJ Open</i> , 2018, 8, e022862.	1.9	22
66	Predicting Outcome in Guillain-Barré Syndrome. <i>Neurology</i> , 2022, 98, .	1.1	22
67	Antiglycolipid antibodies in Guillain-Barré and Fisher syndromes: discovery, current status and future perspective. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 311-318.	1.9	21
68	Guillain-Barré Syndrome Outbreak in Peru 2019 Associated With <i>Campylobacter jejuni</i> Infection. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	20
69	Severe childhood Guillain-Barré syndrome associated with <i>Mycoplasma pneumoniae</i> infection: a case series. <i>Journal of the Peripheral Nervous System</i> , 2015, 20, 72-78.	3.1	17
70	Zika Virus Infection and Guillain-Barré Syndrome in Three Patients from Suriname. <i>Frontiers in Neurology</i> , 2016, 7, 233.	2.4	17
71	Clinical factors, diagnostic delay, and residual deficits in chronic inflammatory demyelinating polyradiculoneuropathy. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 253-259.	3.1	15
72	Comparison of Fc N-Glycosylation of Pharmaceutical Products of Intravenous Immunoglobulin G. <i>PLoS ONE</i> , 2015, 10, e0139828.	2.5	14

#	ARTICLE	IF	CITATIONS
73	Guillain-Barré Syndrome and Campylobacter Infection. , 2014, , 245-261.		13
74	Small volume plasma exchange for Guillain-Barré syndrome in resource poor settings: a safety and feasibility study. Pilot and Feasibility Studies, 2017, 3, 40.	1.2	13
75	Intrathecal antibody responses to GalC in Guillain-Barré syndrome triggered by Mycoplasma pneumoniae. Journal of Neuroimmunology, 2018, 314, 13-16.	2.3	12
76	Clinical relevance of serum antibodies to GD1b in immune-mediated neuropathies. Journal of the Peripheral Nervous System, 2018, 23, 227-234.	3.1	12
77	<scp>IVI</scp>-induced plasmablasts in patients with Guillain-Barré syndrome. Annals of Clinical and Translational Neurology, 2019, 6, 129-143.	3.7	12
78	Boundaries of chronic inflammatory demyelinating polyradiculoneuropathy. Journal of the Peripheral Nervous System, 2020, 25, 4-8.	3.1	12
79	Antecedent infections in <scp>Guillain-Barré</scp> syndrome in endemic areas of arbovirus transmission: A multinational case-control study. Journal of the Peripheral Nervous System, 2021, 26, 449-460.	3.1	12
80	Neuropathophysiological potential of Guillain-Barré syndrome anti-ganglioside-complex antibodies at mouse motor nerve terminals. Clinical and Experimental Neuroimmunology, 2011, 2, 59-67.	1.0	11
81	Guillain-Barré syndrome: surveillance and cost of treatment strategies – Authors' reply. Lancet, The, 2017, 389, 253-254.	13.7	11
82	International chronic inflammatory demyelinating polyneuropathy outcome study (ICOS): Protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome. Journal of the Peripheral Nervous System, 2019, 24, 34-38.	3.1	11
83	Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy after alemtuzumab therapy in kidney transplant recipients. Neurology: Neuroimmunology and Neuroinflammation, 2020, 7, .	6.0	11
84	International Validation of the Erasmus Guillain-Barré Syndrome Respiratory Insufficiency Score. Annals of Neurology, 2022, 91, 521-531.	5.3	11
85	Diagnosis and treatment of Guillain-Barré syndrome during the Zika virus epidemic in Brazil: A national survey study. Journal of the Peripheral Nervous System, 2019, 24, 340-347.	3.1	10
86	Diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy in clinical practice: A survey among Dutch neurologists. Journal of the Peripheral Nervous System, 2020, 25, 247-255.	3.1	10
87	Hospital Admissions, Transfers and Costs of Guillain-Barré Syndrome. PLoS ONE, 2016, 11, e0143837.	2.5	9
88	Acute-onset chronic inflammatory demyelinating polyneuropathy after Zika virus infection. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1118-1119.	1.9	9
89	Antibodies to Protein but Not Glycolipid Structures Are Important for Host Defense against Mycoplasma pneumoniae. Infection and Immunity, 2019, 87, .	2.2	9
90	Guillain-Barré syndrome following SARS-CoV-2 vaccination in the UK: a prospective surveillance study. BMJ Neurology Open, 2022, 4, e000309.	1.6	9

#	ARTICLE	IF	CITATIONS
91	Protocol of a dose response trial of IV immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (DRIP study). <i>Journal of the Peripheral Nervous System</i> , 2018, 23, 5-10.	3.1	8
92	Prediction of disease progression in Miller Fisher and overlap syndromes. <i>Journal of the Peripheral Nervous System</i> , 2017, 22, 446-450.	3.1	7
93	Guillain-Barré syndrome in times of pandemics. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1027-1029.	1.9	7
94	Genetic biomarkers for intravenous immunoglobulin response in chronic inflammatory demyelinating polyradiculoneuropathy. <i>European Journal of Neurology</i> , 2021, 28, 1677-1683.	3.3	7
95	Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values. <i>Clinical Neurophysiology</i> , 2022, 138, 231-240.	1.5	7
96	Epidemiology of chronic inflammatory demyelinating polyradiculoneuropathy in The Netherlands. <i>Journal of the Peripheral Nervous System</i> , 2022, 27, 182-188.	3.1	7
97	Intrathecal Anti-GalC Antibodies in Bickerstaff Brain Stem Encephalitis. <i>Neuropediatrics</i> , 2015, 46, 428-430.	0.6	6
98	Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1080-1088.	1.9	6
99	Acute flaccid myelitis and Guillain-Barré syndrome in children: A comparative study with evaluation of diagnostic criteria. <i>European Journal of Neurology</i> , 2022, 29, 593-604.	3.3	6
100	The legacy of ZikaPLAN: a transnational research consortium addressing Zika. <i>Global Health Action</i> , 2021, 14, 2008139.	1.9	5
101	Guillain-Barré Syndrome in Suriname; Clinical Presentation and Identification of Preceding Infections. <i>Frontiers in Neurology</i> , 2021, 12, 635753.	2.4	4
102	Efficient design and analysis of randomized controlled trials in rare neurological diseases: An example in Guillain-Barré syndrome. <i>PLoS ONE</i> , 2019, 14, e0211404.	2.5	3
103	Association of mannose-binding lectin 2 gene polymorphisms with Guillain-Barré syndrome. <i>Scientific Reports</i> , 2022, 12, 5791.	3.3	3
104	Motor nerve excitability after childhood Guillain-Barré syndrome. <i>Journal of the Peripheral Nervous System</i> , 2017, 22, 100-105.	3.1	2
105	<i>Mycoplasma Pneumoniae</i> and Antibodies against Galactocerebroside in a 9-Year-Old Boy with Encephalitis. <i>Neuropediatrics</i> , 2019, 50, 054-056.	0.6	2
106	Neurofilament light chain as biomarker for axonal damage in Guillain-Barré syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 4-4.	1.9	2
107	Electrophysiology of Guillain-Barré syndrome in Bangladesh: A prospective study of 312 patients. <i>Clinical Neurophysiology Practice</i> , 2021, 6, 155-163.	1.4	2
108	Antibody responses to GalC in severe and complicated childhood Guillain-Barré syndrome. <i>Journal of the Peripheral Nervous System</i> , 2018, 23, 67-69.	3.1	1

#	ARTICLE	IF	CITATIONS
109	Clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside. <i>Annals of Neurology</i> , 2000, 47, 314-321.	5.3	1
110	Diagnosis and management of Guillain-Barré syndrome in ten steps. , 0, .		1
111	Intrathecal Anti-GalC Antibodies in Bickerstaff Brain Stem Encephalitis. <i>Neuropediatrics</i> , 2015, 46, e1-e1.	0.6	0
112	Could Albumin be a Biomarker to Monitor the Effect of Intravenous Immunoglobulin on Guillain-Barré Syndrome?â€”Reply. <i>JAMA Neurology</i> , 2017, 74, 872.	9.0	0
113	Reply to: â€œAssociation of hepatitis E virus infection and myasthenia gravis: A pilot studyâ€• <i>Journal of Hepatology</i> , 2018, 68, 1321-1322.	3.7	0
114	Population Pharmacokinetic Modelling of Intravenous Immunoglobulin Treatment in Patients with Guillain-Barré Syndrome. <i>Clinical Pharmacokinetics</i> , 0, , .	3.5	0